Is Ibrexafungerp safe while breastfeeding?
Here is what NIH LactMed, the U.S. National Library of Medicine's authority on medicines and breastfeeding, reports about Ibrexafungerp. This is a summary of that source — not our own verdict.
Effects on the breastfed infant
Relevant published information was not found as of the revision date.
Effects on milk supply
Relevant published information was not found as of the revision date.
Levels in milk
Maternal Levels. The manufacturer repots a milk-only pharmacokinetic lactation study that evaluated concentrations of ibrexafungerp in the plasma and breast milk of 5 healthy lactating women, who were between 33 and 346 days postpartum. Two oral doses of 300 mg of ibrexafungerp were administered 12 hours apart for one day. Ibrexafungerp was detected in breastmilk with a median peak concentration of 72.22 mcg/L (range 32.1 to 94.1 mcg/L) in the 2- to 4- hour milk collection and an average concentration of 45.39 mcg/L. The mean calculated daily infant dosage was 0.05 mg which is 1% of the maternal weight-adjusted dose or RID.[ 1 ] Infant Levels. Relevant published information was not found as of the revision date.
Alternatives LactMed lists
“No published information” means the studies do not exist yet — not that Ibrexafungerp is known to be harmful, and not that it is known to be safe. Your prescriber or pharmacist can weigh your baby's age and whether a better-studied alternative would do the same job. Worth asking before stopping a medicine you need.
Source: NIH LactMed (National Library of Medicine).
Educational summary of an authoritative source — not medical advice. Never start, stop, or change a medicine while breastfeeding without confirming with your doctor.